Table 1.
Patient characteristics
| Lopinavir group (n = 439) | Atazanavir group (n = 313) | |
|---|---|---|
| Age (years) | 40.5 (35.2–45.7) | 41.8 (37.0–46.9) |
| Gender | ||
| female | 95 (22%) | 54 (17%) |
| male | 344 (78%) | 259 (83%) |
| Ethnicity | ||
| black | 141 (32%) | 75 (24%) |
| white | 298 (68%) | 238 (76%) |
| Weight (kg) | 71.8 (64.5–80.5) | 72.7 (65.0–82.8) |
| Time from last PIa intake (h) | 12 (12–13) | 19 (13–24) |
| Time on PIa (weeks) | 39 (12–99) | 16 (4–36) |
| Time on current regimen (weeks) | 20 (7–49) | 11 (3–28) |
| Dosing schedule | ||
| once daily 400 mg | 0 | 25 (8%) |
| once daily 300 mg + ritonavir | 0 | 187 (60%) |
| once daily 400 mg + ritonavir | 0 | 101 (32%) |
| twice daily 400 mg + ritonavir | 302 (69%) | 0 |
| twice daily 533 mg + ritonavir | 137 (31%) | 0 |
| PIa plasma concentration (ng/mL) | 5358 (3116–8133) | 919 (534–1968) |
| Number of previous PIs before start of PIa | 2 (0–3) | 2 (0–3) |
| PI-naive before start of PIa | 142 (32%) | 89 (28%) |
| Concomitant antiretroviral drugsb | ||
| NRTIs | ||
| zidovudine | 88 (20%) | 40 (13%) |
| lamivudine | 228 (52%) | 114 (36%) |
| stavudine | 40 (9%) | 15 (5%) |
| tenofovir | 212 (48%) | 208 (66%) |
| didanosine | 123 (28%) | 100 (32%) |
| abacavir | 90 (21%) | 91 (29%) |
| emtricitabine | 11 (3%) | 40 (13%) |
| NNRTIs | ||
| nevirapine | 51 (12%) | 23 (7%) |
| efavirenz | 74 (17%) | 30 (10%) |
| PIs | ||
| lopinavir | 439 (100%) | 17 (5%) |
| atazanavir | 7 (2%) | 313 (100%) |
| saquinavir | 67 (15%) | 22 (7%) |
| fosamprenavir | 26 (6%) | 2 (1%) |
| Concomitant TB drug | ||
| no | 424 (97%) | 312 (99.7%) |
| rifabutin | 15 (3%) | 1 (0.3%) |
| rifampicin | 0 | 0 |
PI, protease inhibitor, NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; TB, tuberculosis.
Values are number (%) or median (IQR).
aLopinavir in the lopinavir group; atazanavir in the atazanavir group.
bOnly drugs given in at least 5% of patients in one of the two groups.